Navigation Links
High-Dosage of Epirubicin and Cyclophosphamide may cause AML

Adjuvant chemotherapy with epirubicin and cyclophosphamide for early breast cancer// patients increased the risk of Acute myeloid leukemia or Myelodysplastic syndrome.

Recent study published in Journal of clinical oncology reports that early breast cancer patients undergoing chemotherapy with higher than standard cumulative doses of epirubicin and cyclophosphamide have an increased risk of developing Acute myeloid leukemia (AML) or Myelodysplastic syndrome (MDS).

This study was done by Dr. David Rogers and his team, in which they have proved that patients undergoing adjuvant therapy with higher than standard cumulative doses of epirubicin and cyclophosphamide for early stage of breast cancer are at increased risk of developing AML or MDS. It has been reported that though the long-term survival of these patients as increased following administration of these drugs, but the risk of developing secondary AML with or without MDS has been increased.

Epirubicin monitoring plan was started by Dr. Rogers collaboration with Gruppo Pfizer of Milan, Italy to undergo 19 randomized clinical trials for adjuvant therapy in early breast cancer, the study included 9796 patients started in early 1984, with follow up till 2001. In this follow-up study 30 patients developed AML/MDS. Both the cumulative doses of epirubicin and cyclophosphamide had independent risk factors for AML/MDS. Other factors such as age, radiotherapy, granulocyte colony stimulating factor and tamoxifen were not independently associated with AML/MDS.

Patients taking more than the standard cumulative dose of epirubicin was found to have an increased relative risk of 6.80. The standard dose of epirubicin was found to be 720 mg/m. For doses no higher than the standard dose, "the low risk of secondary leukemia does not differ significantly from the risk in patients not treated with epirubicin or who received hormonal therapy only," Dr. Rogers' team notes.

Both epi rubicin and cyclophosphamide were usually administered in combination and the 4760 patients who received the standard doses of epirubicin and cyclophosphamide (6300 mg/m), the 8-year cumulative probability of developing AML/MDS was 0.37%, compared with 4.97% of the 261 patients who received higher cumulative doses of both drugs.

"In clinical practice, the described regimens have a strong benefit to risk ratio," the authors conclude, "and patients and clinicians can be reassured that the risk of leukemia is likely to be low if the cumulative doses of these regimens are not exceeded."
'"/>




Related medicine news :

1. Kissing can cause Kaposi’s Sarcoma in AID
2. Kidney Stones - Interesting New Research implicates bacteria as its cause
3. Roller coasters – cause “Chronic Headache?
4. Starvation in pregnant women can cause heart disease to their children
5. And now they say infections can cause heart disease!!!!
6. And now they say infections can cause heart disease!!!!
7. Ticks may cause more diseases
8. Depression may cause delayed wound healing
9. Analgesic abuse - cause for chronic headache in children
10. Strong pain killers likely to cause miscarriage
11. Pressure on spine cause problems
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... ... 2016 , ... David J. Dykeman , Ginger Pigott , and ... speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport Beach in California. ... firm’s global Life Sciences & Medical Technology Group have been featured speakers at every ...
(Date:12/8/2016)... Tampa, Fla (PRWEB) , ... December 08, 2016 ... ... offering smarter modes of access for customers and employees that are both engaging ... ChangeGear 7 with Service Smart Technology, the software company revealed today its plans ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased ... a convenient service for Texas, they are expanding their presence in Dallas. One of ... spree that will bring new jobs to the Dallas and Forth Worth market. STAT ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged to ... mind, SIGVARIS has created a new line of anti-embolism stockings to help prevent ... the benefits of graduated compression when transitioning from recovery to early rehabilitation. , ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... AMSTERDAM , December 8, 2016 Information ... TM metrics in Scopus , the world,s largest ... free access to comprehensive metrics for journals from over 5,000 publishers. ... publish, which journals to subscribe to and when to adjust a ... , , ...
(Date:12/8/2016)... 2016 According to the research report, ... is expected to be worth US$9.7 bn by the ... Between the forecast years of 2016 and 2024, the global ... The leading players operating in the global diabetes injection pens ... plc., Biocon Ltd., and Sanofi S.A. Transparency Market Research reports ...
(Date:12/8/2016)... 2016 According to a new market research report ... Therapeutic (Pain, Insulin)), End Use (Sports, Fitness, RPM), Type (Smart watch, Patch), ... global market, in terms of value, is projected to reach 12.14 Billion ... 18.0% during the forecast period. Continue Reading ... ...
Breaking Medicine Technology: